Ulrich Gergs

Future GLP-1 receptor co-agonists and their cardiac effects

Agonists at glucagon-like-peptide-1 receptors (GLP-1R) are becoming approved drugs to treat not only type 2 diabetes and obesity but also cardiac diseases such as coronary heart disease, myocardial infarction and heart failure. Agonism at the GLP-1R can be combined with agonism a...

Contractile effects of Aficamten in the human atrium

Abstract Aficamten is an approved drug to treat hypertrophic cardiomyopathy. Aficamten desensitizes bovine myofilaments against calcium cations. In isolated animal cardiac preparations, aficamten reduced force of contraction (FOC) but its effects on isolated human cardiac prepara...